An interesting article recently published in Science Translational Medicine reports a variable risk of persistent COVID-19 among patients affected by different immunodeficiency conditions. The aforementioned paper’s authors also suggest that suppression of both B and T cell responses is associated with the highest risk of a prolonged SARS-CoV-2 infection [1].
Noteworthy, measles virus (MeV) is a highly lymphotropic pathogen infecting long-lived bone marrow plasmacells. By doing so, MeV may cause a prominent drop in the host’s preexisting antibody response against other infectious agents [2]. This will obviously result in a lower resistance to natural infection as well as in a diminished protection offered by vaccine immunization against the aforementioned pathogens.
Such a peculiar, MeV-induced mechanism of immune amnesia could also putatively affect SARS-CoV-2 evolution, considering also the viral variants which have already shown a high propensity to escape the immunity conferred by natural infection and/or vaccination [3]. Consequently, the global success achieved against COVID-19 thanks to mass vaccine immunization could turn out to be even more adversely affected.
Regretfully, following a significant drop in children’s vaccination campaigns throughout the COVID-19 pandemic, a skyrocketing increase in measles disease cases has been observed in 2023 in Europe (including Italy) and, to a lesser extent, in extra-European Countries compared with 2022 [4]. This reduction in the European pediatric population’s active immunization had already resulted in an 18% increase in estimated disease cases and in a 43% increase in measles fatalities in 2022 compared with 2021, according to a report released last November by the World Health Organization [5]. This should be a top priority in the global fight against an infectious disease causing over 100,000 deaths worldwide, with mass vaccinations against measles between 2000 and 2021 having saved approximately 57 million lives [5].
In conclusion, an extensive measles vaccine coverage of the general pediatric population is urgently needed on a global scale, with international and national Health Authorities putting their best efforts and encouragement forward in this direction.
Conflicts of Interest
The author declares no conflicts of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Li Y., Choudhary M.C., Regan J., Boucau J., Nathan A., Speidel T., Liew M.Y., Edelstein G.E., Kawano Y., Uddin R., et al. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci. Transl. Med. 2024;16:eadk1599. doi: 10.1126/scitranslmed.adk1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mina M.J., Kula T., Leng Y., Li M., De Vries R.D., Knip M., Siljander H., Rewers M., Choy D.F., Wilson M.S., et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366:599–606. doi: 10.1126/science.aay6485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Di Guardo G. COVID-19: Measles and Antibiotic Resistance Are a Matter of Concern. Pathogens. 2021;10:449. doi: 10.3390/pathogens10040449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Minta A.A., Ferrari M., Antoni S., Portnoy A., Sbarra A., Lambert B., Hatcher C., Hsu C.H., Ho L.L., Steulet C., et al. Progress toward Measles Elimination—Worldwide, 2000–2022. Wkly. Epidemiol. Rec. 2023;72:1262–1268. doi: 10.15585/mmwr.mm7246a3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wong C. Measles outbreaks cause alarm: What the data say. Nat. News Explain. 2024 doi: 10.1038/d41586-024-00265-8. [DOI] [PubMed] [Google Scholar]